← Back to Screener
Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX)
Price$3.60
Favorite Metrics
Price vs S&P 500 (26W)-42.41%
Price vs S&P 500 (4W)7.13%
Market Capitalization$1.98B
All Metrics
Book Value / Share (Quarterly)$2.14
P/TBV (Annual)2.59x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)23.30%
Cash Flow / Share (Quarterly)$-0.72
Price vs S&P 500 (YTD)-10.96%
Gross Margin (TTM)4.99%
Net Profit Margin (TTM)-863.35%
EPS (TTM)$-1.48
10-Day Avg Trading Volume10.28M
EPS Excl Extra (TTM)$-1.48
Revenue Growth (5Y)79.93%
EPS (Annual)$-1.44
ROI (Annual)-56.09%
Gross Margin (Annual)4.99%
Net Profit Margin (5Y Avg)-964.06%
Cash / Share (Quarterly)$1.41
Revenue Growth QoQ (YoY)681.74%
ROA (Last FY)-43.74%
Revenue Growth TTM (YoY)26.92%
EBITD / Share (TTM)$-1.30
ROE (5Y Avg)-51.25%
Operating Margin (TTM)-880.85%
Cash Flow / Share (Annual)$-0.72
P/B Ratio1.75x
P/B Ratio (Quarterly)1.88x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)16.82x
Net Interest Coverage (TTM)-63.75x
ROA (TTM)-47.05%
EPS Incl Extra (Annual)$-1.44
Current Ratio (Annual)5.50x
Quick Ratio (Quarterly)5.42x
3-Month Avg Trading Volume18.99M
52-Week Price Return-31.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.56
P/S Ratio (Annual)26.53x
Asset Turnover (Annual)0.05x
52-Week High$7.18
Operating Margin (5Y Avg)-980.12%
EPS Excl Extra (Annual)$-1.44
CapEx CAGR (5Y)2.10%
26-Week Price Return-38.42%
Quick Ratio (Annual)5.42x
13-Week Price Return-22.04%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)5.50x
Enterprise Value$1,256.495
Revenue / Share Growth (5Y)46.90%
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-863.53%
Cash / Share (Annual)$1.41
3-Month Return Std Dev62.90%
Net Income / Employee (TTM)$-1
ROE (Last FY)-57.01%
Net Interest Coverage (Annual)-41.35x
EPS Basic Excl Extra (Annual)$-1.44
Receivables Turnover (TTM)258.80x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-1.48
Receivables Turnover (Annual)2343.71x
ROI (TTM)-62.62%
P/S Ratio (TTM)26.53x
Pretax Margin (5Y Avg)-966.30%
Revenue / Share (Annual)$0.17
Tangible BV / Share (Annual)$1.56
Price vs S&P 500 (52W)-61.77%
Year-to-Date Return-8.31%
5-Day Price Return13.29%
EPS Normalized (Annual)$-1.44
ROA (5Y Avg)-38.13%
Net Profit Margin (Annual)-863.35%
Month-to-Date Return22.15%
Cash Flow / Share (TTM)$-1.38
EBITD / Share (Annual)$-1.38
Operating Margin (Annual)-880.86%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-50.78%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.48
P/TBV (Quarterly)2.59x
P/B Ratio (Annual)1.88x
Pretax Margin (TTM)-863.53%
Book Value / Share (Annual)$2.14
Price vs S&P 500 (13W)-22.73%
Beta1.12x
Revenue / Share (TTM)$0.14
ROE (TTM)-63.98%
52-Week Low$2.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.71
3.71
3.71
3.71
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock | 26.53x | 26.92% | 4.99% | — | $3.60 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Recursion Pharmaceuticals is a clinical-stage biotech company that integrates computational and experimental technologies—including chemistry, automation, and data science—to accelerate drug discovery and industrialize development. The platform aims to decode biological processes and de-risk the path from research to therapeutic approval. U.S. operations represent the company's primary revenue source, with additional presence in the United Kingdom and other markets.